ClinicalTrials.gov API v2 · 登记更新· Fudan University·· 2 天前
肿瘤学：A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
AI 导读
原文摘录：This is a prospective, single-arm study in patients with locally advanced or metastatic pancreatic cancer that cannot be treated with surgery. The study is planned to enroll 42 patients.
来源：ClinicalTrials.gov API v2 · 登记更新 · clinicaltrials.gov